Michael Makris/LinkedIn
Sep 3, 2025, 03:05
Insights from Michael Makris: FAERS Reveals Thrombotic Events for Marstacimab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, UK. Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, has shared a post on LinkedIn:
“The FDA Adverse Event Reporting System (FAERS) has launched a public dashboard. I thought I would give it a try by looking at what has been reported so far for the ‘rebalancing’ agents.
I was interested to see 3 thrombotic events for marstacimab (Hympavzi). I do not know if one of these is the thrombotic event reported at EAHAD 2025, or whether that was a 4th event. My contacts tell me that the event reported at EAHAD 2025 was in a patient outside the USA.”
Read for more.
Stay informed with Hemostasis Today.
-
Dec 7, 2025, 18:43ASH25 Day 2: Don’t Miss The Highlights
-
Dec 7, 2025, 17:01Abdul Mannan: How Do You Manage a Major Surgery When Blood Transfusion is Impossible?
-
Dec 7, 2025, 16:51Ahmed Bahi on Lina Merghani’s Critique of Early Withdrawal of Aspirin after PCI
-
Dec 7, 2025, 16:30Eloïse Laouenan Presents the Results of HEMOTHEPP-CHU Brest-GETBO Prospective Study
-
Dec 7, 2025, 16:21Jonathan Douxfils: Can We Estimate the VTE Risk of a Pill Before a Million Women Use It?
-
Dec 7, 2025, 16:06Pablo Corral on Why Early LDL-C Reduction Saves Lives
-
Dec 7, 2025, 15:53Paul Batty Congratulates Giulia Simini on Taking The Joint BSH-ASH Abstract Award
-
Dec 7, 2025, 15:35Federica Fogacci Presents The New ILEP Consensus Paper
-
Dec 7, 2025, 15:20Deep Molecular Modeling for Type 2A VWD from Omid Seidizadeh